Target- |
MechanismMolecular chaperones modulators [+1] |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date20 Sep 2024 |
A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis
A multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of arimoclomol in amyotropic lateral sclerosis (ALS)
100 Clinical Results associated with Zevra Denmark A/S
0 Patents (Medical) associated with Zevra Denmark A/S
100 Deals associated with Zevra Denmark A/S
100 Translational Medicine associated with Zevra Denmark A/S